Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus placebo added to insulin glargine in adults with type 2 diabetes mellitus
2008-003843-36Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide + insulin glargine with Placebo + insulin glargine (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 30. Started Oct 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-003843-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003843-36.